US FDA Proposes New ‘Inter-Pandemic’ Pathway For Updating Flu Vaccines

The threat of a highly pathogenic avian influenza pandemic spurred the FDA to have its vaccine advisory committee comment on a new process to update licensed prototype pandemic flu vaccines.

close up of a hand holding a vial labeled h5n1 vaccine
The VRBPAC will comment on a new inter-pandemic process for updating prototype pandemic influenza vaccines during a 10 October meeting. • Source: Shutterstock

The US Food and Drug Administration wants advisory committee input on a new “inter-pandemic” process for updating licensed prototype pandemic influenza vaccines that is designed to make better-matched shots available prior to a pandemic.

More from Vaccines

Almost Public: Interagency Meeting Replaces US FDA ‘25-’26 Flu Vaccine AdComm

 

Only government staff participated in the meeting defining the next season’s influenza vaccine composition after the annual public FDA vaccines advisory committee meeting was cancelled.

Makary US FDA Nomination Advances, Last Minute Hiccup May Offer Clues On Mifepristone

 

President Trump’s CDC director nominee was pulled after vaccine positions appeared too extreme for some Republicans, but the nominations to lead the FDA and NIH advanced to the Senate floor despite last-minute drama.

Senators Scrutinize US FDA Commissioner Nominee Makary Over VRBPAC Cancellation

 
• By 

Martin Makary said he would re-evaluate the topics that deserve a Vaccines and Related Biological Products Advisory Committee review, but did not commit to rescheduling the cancelled meeting on influenza vaccine strain selection.

Science Vs. Politics: Hearing Could Reveal Makary’s Approach To Unusual Administration Involvement

 

US FDA Commissioner nominee Martin Makary’s 6 March Senate confirmation hearing should offer insight on his alignment with HHS Secretary Robert F. Kennedy Jr.'s views and willingness to insulate the FDA from an unusual level of micromanagement by the department and White House.

More from Product Reviews

Vertex Non-Opioid Pain Drug Draws Bipartisan Support In House Hearing

 

Congress continues to offer broad support for encouraging alternatives to opioid pain medicine, including proposals to speed coverage of new agents like Vertex’ Journavx.

US FDA Spikes Vanda’s Hetlioz For Insomnia, Lack Of Well-Controlled Trial ‘Fatal’

 
• By 

Acting Commissioner Sara Brenner rejected the company’s request for a hearing, saying the lack of an adequate and well-controlled trial showing tasimelteon's effectiveness in treating sleep-onset insomnia is “fatal to the application.”

EU CHMP Opinions And MAA Updates

 

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.